The Role of IgM-Enriched Immunoglobulin (Pentaglobin) in Septic Patients with Hematological Disease
Background: Patients with hematological disease are 15 times more likely to develop sepsis than the general population. The patient with hematological disease and, mainly, those undergoing hematopoietic stem cell transplantation (HSCT), develop a severe secondary humoral immunodeficiency, with low serum levels of IgM, which may take more than a year to be restored.
Materials and Methods: This is a retrospective, controlled and observational study that analyzed 51 patients with underlying hematological disease, who were diagnosed with sepsis or septic shock during the study period, to evaluate whether IgM-rich Ig replacement decreases the 30-day mortality.
Results: Of the 51 patients, 35 patients received IgM-rich immunoglobulin (group A) and 16 (31%) received conventional therapy. Eleven (69%) patients in the control group were alive after 30 days compared to 11 (34%) patients in the intervention group, p= 0.013.
Conclusion: There are no apparent benefits in the use of IgM-rich immunoglobulin in septic patients with hematological disease.
2. Bayraktar UD, Nates JL. Intensive care outcomes in adult hematopoietic stem cell transplantation patients. World J Clin Oncol. 2016;7(1):98-105.
3. Roze des Ordons AL, Chan K, Mirza I, et al. Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control stude. BMC Cancer. 2010;10:516.
4. Pène F, Soares M. Can we still refuse ICU admission of patients with hematological malignancies? Intensive Care Med. 2008;34(5):790-2.
5. Pène F, Percheron S, Lemiale V, et al. Temporal changes in management and outcomes of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008;36(3):690-6.
6. Lacerda JF. Immunologic reconstitution after allogeneic stem cell transplant. Acta Med Port. 2004;17(6):471-80.
7. Kakoullis L, Pantzaris ND, Platanaki C, et al. The use of IgM-enriched immunoglobulin in adult patients with sepsis. J Crit Care. 2018;47:30-5.
8. Cui J, Wei X, Lv H, et al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care. 2019; 9(1):27.
9. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.
10. Werdan K. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Ther Apher. 2001; 5(2):115–22.
11. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med. 1991;19(9):1104-13.
12. Hentrich M, Fehnle K, Ostermann H, et al. IgMA-enriched imunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial. Crit Care Med. 2006; 34(5):1319-25.
|Issue||Vol 15, No 2 (2021)|
|Pentaglobin; Sepsis; Hematological disease|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|